CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Adalimumab

Adalimumab

Last Updated: September 13, 2018

Result type: Reports

Project Number: SR0455-000

Product Line: Reimbursement Review

Generic Name: Adalimumab

Brand Name: Humira

Manufacturer: AbbVie Corporation

Therapeutic Area: Hidradenitis suppurativa

Indications: Hidradenitis suppurativa

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 19, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions

Adalimumab

Files